Cancer Genetics and Cellaria Partner on Precision Medicine Tools
October 08 2018 - 7:00AM
Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision
medicine for immuno-oncology and genomics through molecular markers
and diagnostics, and Cellaria, LLC, a scientific innovator that
develops revolutionary new cancer models, today announced a new
collaboration to develop extensive precision medicine tools and
platform technologies to support the development of new cancer
therapeutics.
Cancer Genetics will deploy its Genomics Center of Excellence to
characterize Cellaria’s pipeline of commercial and custom-developed
biopharma products. Cancer Genetics will leverage its biomarker and
genomics testing capabilities to better understand patient
diversity across clinical disease categories. The combination of
Cellaria’s in vitro expertise and Cancer Genetics’s pharmacology
expertise will create innovative models that provide detailed, and
patient-specific, assessment of response to therapy. The companies
will concentrate their genomics testing and pharmacology
development efforts on solid tumors in both primary and metastatic
disease.
John A. Roberts, chief executive officer of Cancer Genetics,
commented, “This collaboration came about as part of our 2018
transformation strategy. The addition of Cellaria as a channel
partner and access to their in vitro capabilities will greatly
enhance our preclinical and biopharma offerings. We are also
looking forward to utilizing our genomics and pharmacology services
to develop novel, and informative, oncology models for Cellaria and
Cellaria’s biopharma clients that will accelerate their drug
discovery and development efforts.”
David Deems, chief executive officer of Cellaria, said,
“Cellaria has a unique business model of generating innovative in
vitro disease models which mimick patients’ tumor biology. These
models are crucial for accelerating therapeutic research and
personalized medicine. The opportunity to collaborate with
Cancer Genetics to leverage their robust genomics centers and
pharmacology capabilities will advance our mission of building
comprehensive and accurate tools for precision oncology.”
ABOUT CELLARIA
Cellaria creates breakthrough disease models that reflect the
unique nature and complexity of a patient. Using these informative
models, disease researchers are better able to select promising
compounds and work towards personalized approaches that would
enable physicians to identify the most effective treatment for each
patient’s needs. Cellaria’s innovative products help lead the
research community to more personalized therapeutics,
revolutionizing and accelerating the search for a cancer cure. For
more information, visit www.cellariabio.com. You can learn more
about our cell models here.
ABOUT CANCER GENETICS
Cancer Genetics, Inc. is a leader in enabling precision medicine
in oncology from bench to bedside through the use of oncology
biomarkers and molecular testing. Cancer Genetics is developing a
global footprint with locations in the US, Australia and China. We
have established strong clinical research collaborations with major
cancer centers such as Memorial Sloan Kettering, The Cleveland
Clinic, Mayo Clinic, Keck School of Medicine at USC and the
National Cancer Institute.
The Company offers a comprehensive range of laboratory services
that provide critical genomic and biomarker information. Its
state-of-the-art reference labs are CLIA-certified and
CAP-accredited in the US and have licensure from several states
including New York State.
For more information, please visit or follow Cancer
Genetics at:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward Looking Statements:
This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements pertaining to future financial
and/or operating results, future growth in revenues, margins,
research, technology, clinical development and potential
opportunities for Cancer Genetics, Inc. tests and services, along
with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements.
Any statements that are not historical fact
(including, but not limited to, statements that contain words such
as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, risks
of cancellation of customer contracts or bookings or discontinuance
of trials, risks that anticipated benefits from acquisitions will
not be realized, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
maintenance of intellectual property rights, uncertainty of
collections from Medicare and third party payors for novel tests
and services and other risks discussed in the Cancer Genetics, Inc.
Form 10-K for the year ended December 31, 2016 along with other
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. Cancer
Genetics, Inc. disclaims any obligation to update these
forward-looking statements.
Investor Contacts:Lee Roth / Carol Ruth The
Ruth GroupTel: 646-536-7012 / 7004Email: lroth@theruthgroup.com /
cruth@theruthgroup.com
Media Contact:Kirsten ThomasThe Ruth GroupTel:
508-280-6592Email: kthomas@theruthgroup.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2023 to Aug 2024